SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan
Main finding · Incident CKDResult — go to the resultAdjusted hazard ratio 0.86 95% CI 0.83–0.89Authors' conclusion
In patients with T2D without preexisting CKD, SGLT2 inhibitor use was associated with reduced risks of kidney disease, cardiovascular events, and mortality.
Study context
- Population
- Patients with T2D without preexisting chronic kidney disease (CKD), Taiwan's National Health Insurance Research Database (2016–2021)11,617 matched pairs
- Participants
- 11,617 vs 11,617
- Exposure
- SGLT2i users vs non-users
- SGLT2 inhibitor usersn = 11,617
- Non-usersn = 11,617reference
- Outcome
- Incident CKD
Methodological detailsretrospective cohort study, nationwide, 1:1 propensity score matching
- Retrospective cohort study
- Nationwide
- 1:1 propensity score matching
Main finding
As reported in the abstract
Adjusted hazard ratio
0.86
95% CI 0.83–0.89
SGLT2i usersvs Non-users
aHR 0.86 (95% CI 0.83–0.89)
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| All-cause mortality | 0.73 (0.64–0.82) | |
| 0.512Adjusted hazard ratio (log scale) |
- All-cause mortality: 1:1 propensity score matched
Macroalbuminuria
- SGLT2 inhibitor use: aHR for macroalbuminuria
- 0.85 (95% CI 0.82-0.89)
- 1:1 propensity score matched
Acute kidney injury
- SGLT2 inhibitor use: aHR for acute kidney injury
- 0.71 (95% CI 0.59-0.86)
- 1:1 propensity score matched
Dialysis
- SGLT2 inhibitor use: aHR for dialysis
- 0.46 (95% CI 0.20-1.06)
- 1:1 propensity score matched
MACE
- aHR for MACE
- 0.84 (95% CI 0.76-0.92)
- 1:1 propensity score matched
Hospitalisation for HF
- aHR for hospitalisation for HF
- 0.85 (95% CI 0.76-0.96)
- 1:1 propensity score matched
MI
- aHR for MI
- 0.68 (95% CI 0.52-0.89)
- 1:1 propensity score matched
Original publication
SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan. Diabetes Res Clin Pract. Published 17 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →